ReviewCurrent urology reports2008
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
Review in Current urology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03888742 (A Cross Sectional Study to Assess the Effect of Androgen Deprivation Therapy on Gut and Urinary Microbiota in Patients With Prostate Cancer), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Cross Sectional Study to Assess the Effect of Androgen Deprivation Therapy on Gut and Urinary Microbiota in Patients With Prostate Cancer
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Trial
- Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Trial
- Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.The Journal of urology · 2011Trial
- Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.The Journal of urology · 2010Trial
- Association Between Diabetes and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis of Observational Studies.The world journal of men's health · 2025Article
- A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.Prostate cancer and prostatic diseases · 2021Article
- Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.Current urology reports · 2017Review
- Androgen receptor (AR) in cardiovascular diseases.The Journal of endocrinology · 2016Review
- Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States.Annals of epidemiology · 2011Article
- Clinical utility of denosumab for treatment of bone loss in men and women.Clinical interventions in aging · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.